1.21
price up icon4.31%   0.05
pre-market  Pre-mercato:  1.21  
loading
Precedente Chiudi:
$1.16
Aprire:
$1.15
Volume 24 ore:
1.08M
Relative Volume:
1.74
Capitalizzazione di mercato:
$18.40M
Reddito:
$486.00K
Utile/perdita netta:
$-28.43M
Rapporto P/E:
-0.4292
EPS:
-2.8189
Flusso di cassa netto:
$-26.75M
1 W Prestazione:
-9.02%
1M Prestazione:
+35.96%
6M Prestazione:
-56.32%
1 anno Prestazione:
-43.19%
Intervallo 1D:
Value
$1.10
$1.265
Intervallo di 1 settimana:
Value
$1.10
$1.38
Portata 52W:
Value
$0.85
$4.30

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
Nome
Vyne Therapeutics Inc
Name
Telefono
800-775-7936
Name
Indirizzo
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
Dipendente
13
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
VYNE's Discussions on Twitter

Confronta VYNE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VYNE
Vyne Therapeutics Inc
1.21 22.16M 486.00K -28.43M -26.75M -2.8189
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-11-18 Iniziato BTIG Research Buy
2021-12-06 Ripresa H.C. Wainwright Buy

Vyne Therapeutics Inc Borsa (VYNE) Ultime notizie

pulisher
07:16 AM

Is VYNE Therapeutics Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com

07:16 AM
pulisher
12:56 PM

What drives VYNE Therapeutics Inc. stock priceConsistently profitable trades - Autocar Professional

12:56 PM
pulisher
Jul 21, 2025

What analysts say about VYNE Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

VYNE Therapeutics Inc. Stock Analysis and ForecastSuperior profit margins - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Does VYNE Therapeutics Inc. stock pay reliable dividendsFree Capital Allocation Plans - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

How VYNE Therapeutics Inc. stock performs during market volatilityShort Term High Return Strategy - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

Why VYNE Therapeutics Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes VYNE Therapeutics Inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

VYNE Therapeutics: A High-Stakes Gamble on Vitiligo and Psoriasis - AInvest

Jul 11, 2025
pulisher
Jul 08, 2025

Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% – Should You Sell? - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

VYNE Unblinds Early VYN202 Data After Safety Pause - Dermatology Times

Jul 07, 2025
pulisher
Jul 03, 2025

BTIG reiterates Buy rating on VYNE Therapeutics stock ahead of vitiligo trial data - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

H.C. Wainwright reiterates Buy rating on VYNE Therapeutics stock amid clinical hold update - Investing.com Canada

Jul 03, 2025
pulisher
Jul 02, 2025

NOVT secures new $1B credit facility, extends maturity to 2030 | VYNE SEC FilingForm 4 - Stock Titan

Jul 02, 2025
pulisher
Jul 02, 2025

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - The Manila Times

Jul 02, 2025
pulisher
Jul 02, 2025

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 | VYNE Stock News - GuruFocus

Jul 02, 2025
pulisher
Jun 26, 2025

VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14% - Nasdaq

Jun 26, 2025
pulisher
Jun 25, 2025

Celebrating World Vitiligo Day 2025 with Dermatology Times - Dermatology Times

Jun 25, 2025
pulisher
Jun 20, 2025

Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail

Jun 20, 2025
pulisher
Jun 18, 2025

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World

Jun 18, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 09, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 04, 2025
pulisher
May 30, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World

May 30, 2025
pulisher
May 29, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India

May 29, 2025
pulisher
May 25, 2025

VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World

May 25, 2025
pulisher
May 20, 2025

VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com

May 20, 2025
pulisher
May 11, 2025

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 11, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
May 09, 2025

VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks

May 08, 2025
pulisher
May 08, 2025

Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

May 08, 2025
pulisher
Apr 28, 2025

VYNE Therapeutics Inc (VYNE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Closing Strong: VYNE Therapeutics Inc (VYNE) Ends at 1.43, Down -23.94 from Last Close - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

Apr 28, 2025

Vyne Therapeutics Inc Azioni (VYNE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Capitalizzazione:     |  Volume (24 ore):